| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (frommouse) |
| Target | CD44 v6 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| (verify) | |
Bivatuzumab (previouslyBIWA 4) is a humanizedmonoclonal antibody againstCD44 v6.[1][2]
It is officially described as "immunoglobulin G1 (human-mouse monoclonal BIWA4 γ1-chain anti-human antigen CD44v6), disulfide with human-mouse monoclonal BIWA4 κ-chain, dimer".[3] Prior to 2002 it was described as targeting CD44 v8.[4]
It has been chemically linked to various radioisotopes for use in radiotherapy for, e.g. inoperable recurrent or metastatichead and neck cancer.[1]
It has also been linked to a cytotoxic drugmertansine to formbivatuzumab mertansine.
 | Thismonoclonal antibody–related article is astub. You can help Wikipedia byexpanding it. |
